HPV siRNA

본문 바로가기

HPV siRNA

The expression of the carcinogenic genes of Human Papilloma Virus (HPV) results in variety of cancers, such as head and neck cancer, cervical cancer, genital cancer and etc. Our HPV siRNA is a new drug that cures cancer by simultaneously inhibiting the expression of the E6/E7 genes of HPV as a nucleic acid agent, and it can maximize its effectiveness by combined prescription with chemotherapy and radiation therapy.

HPV siRNA
  • Development of siRNA agent as anticancer agent by inhibiting E6/E7 protein expressed in HPV (Human Papilloma Virus) 16/18 type.
  • IP secured in 3 step; Hit – Candidate – siRNA Pool
Characteristics of HPV siRNA
  • Synergistic anticancer therapeutic effect according to the functional recovery of the tumor suppressor gene (TP53, Rb)
  • Sensitizer for combination treatment
  • No off-target effect (OTE)
Development goals and strategies
  • Development of targeted agent (first-in-class) to target HPV (+), which is leading cause of head and neck cancer
  • Patient selection biomarker-based companion diagnostics
  • US FDA approved
Patents
  • Composition for treatment of cervix cancer (KR, PCT, US)
  • Composition for treatment of HPV-related cancers (AU, BR, CA, CN, EP, IN, JP, KR, MX, PCT, RU, UA, US)
  • Method for maintaining increased intracellular p53 level, induced by platinum-based anticancer drug, and application thereof (PCT, KR, CN, US)
  • Sensitizing composition for cancer comprising an agent inhibiting expression of oncogenes of HPV virus (KR, PCT, IN, EP, CN, US)
Ph. D. Thesis
  • Hung Soon Jung. Human Papillomavirus E6/E7 siRNA sensitizer in cervical squamous cell carcinoma. College of Pharmacy, Seoul National University, Seoul, South Korea (2011).
  • Nirmal Rajasekaran. Combination of HPV E6/E7 siRNA and chemo-/radio-therapy: A promising future therapeutic for cervical carcinomas. College of Pharmacy, Seoul National University, Seoul, South Korea (2017)
Publications
  • HS Jung and YK Shin. The potential RNAi-based combination therapeutics. Archives of pharmacal research. 34 (1), 1-2. doi:0.1007/s12272-011-0100-9 (2011)
  • HS Jung et al. The synergistic therapeutic effect of cisplatin with Human papillomavirus E6/E7 short interfering RNA on cervical cancer cell lines in vitro and in vivo. International journal of cancer. 130 (8), 1925-1936. doi:10.1002/ijc.26197 (2011)
  • HS Jung et al. Human papillomavirus: Current and future RNAi therapeutic strategies for cervical cancer. Journal of clinical medicine. 4 (5), 1126-1155. doi:10.3390/jcm4051126 (2015)
  • HS Jung et al. Human Papillomavirus E6/E7-Specific siRNA potentiates the effect of radiotherapy for cervical cancer in vitro and in vivo. International journal of molecular sciences. 16, 12243-12260. doi:10.3390/ijms160612243 (2015)
  • Nirmal R et al. Effect of HPV E6/E7 siRNA with chemotherapeutic agents on the regulation of TP53/E2F dynamics for cell fate decisions. Neoplasia. 19 (10), 735-749. doi:10.1016/j.neo.2017.07.005​ (2017)
  • DG Lim et al. Polyamidoamine-Decorated Nanodiamonds as a Hybrid Gene Delivery Vector and siRNA Structural Characterization at the Charged Interfaces.  ACS applied materials & interfaces. 9 (37), 31543–31556. doi:10.1021/acsami.7b09624  (2017)​